Illinois quietly expanded coverage of costly GLP-1 drugs to 55,000 state employees, and Governor J.B. Pritzker now says he uses one himself.
Story Highlights
- Pritzker confirmed GLP-1 use and said Illinois covers these drugs for 55,000 state workers.
- Illinois expanded eligibility under the state plan in 2023 to include popular GLP-1 drugs.
- A report put the state’s GLP-1 spending at $147 million in fiscal year 2025.
- Records do not show whether taxpayers paid Pritzker’s own prescription costs.
What Pritzker Said About His GLP-1 Use and State Coverage
CBS reporting says Governor J.B. Pritzker acknowledged using a GLP-1 medication and losing about 80 pounds. He said Illinois covers GLP-1 drugs for about 55,000 state employees through the state insurance plan. He also said the policy came before he began injections and framed it as a general benefit decision, not a personal perk. Pritzker linked his coverage path to a past diabetes diagnosis, while also noting the wider weight-loss eligibility that now exists under the plan.
Local coverage shows Illinois broadened access in July 2023 under the state’s group plan to include drugs like Wegovy, Mounjaro, and Ozempic. Another report described state-employee coverage for adults diagnosed with prediabetes, gestational diabetes, or obesity, beginning in mid-2024. Those rules mean the plan covers more than diabetes care. It now reaches some non-diabetes weight-loss cases. That shift matches a nationwide debate over whether public plans should pay for costly anti-obesity drugs.
What It Costs and Who Pays the Bill
NPR Illinois reported that the state’s expanded GLP-1 coverage cost $147 million in fiscal year 2025. Analysts and outlets have warned that list prices are high, often around four figures per month without discounts, which can strain budgets. A political outlet said the governor’s office once projected $210 million for a full year, while some economists warned costs could be higher, though those figures are separate from the $147 million reported spend. These numbers fuel questions about long-run taxpayer exposure.
The record gathered here does not show if taxpayers paid Pritzker’s own prescription bill. Coverage confirms he used a GLP-1 and that the state plan covers them. It does not include his enrollment file, claims records, or cost-sharing details. Without those documents, we cannot say how much, if any, of his medication cost was funded by taxpayers. The broader spending figure reflects program-wide use, not the governor’s individual share.
Why This Touches a Nerve Across Party Lines
Many readers, left and right, see a pattern: leaders set benefits that regular people struggle to get elsewhere. Most employer plans still limit GLP-1s for weight loss, while some states add coverage as costs climb. Here, the governor’s personal use and the state’s policy landed in the same spotlight. Supporters call it smart public health. Critics see a fairness gap, with high drug costs socialized across taxpayers while elites face fewer barriers. Both concerns can be true at once.
Illinois Gov. J.B. Pritzker invited US into his private residence at the Governor's Mansion to share something he's kept private until now.
For the last two years, Pritzker has used a GLP-1 medication to lose 80 pounds, a decision shaped by losing his father to a heart attack… pic.twitter.com/KQFCuCZ6Lu
— David Begnaud (@DavidBegnaud) September 21, 2026
Fair questions remain. Did the state vet the policy with a full actuarial review? Are there guardrails to keep costs from spiking? Could sustained use lower future expenses by cutting diabetes complications, missed work, and hospital stays? Pritzker has argued coverage could save money over time, but the compiled reports here do not include a completed audit proving or disproving that claim. Clear, public data would help citizens judge whether the benefit is prudent or a burden.
What to Watch Next
Watch for formal cost studies from Illinois that model savings and risks over several years. Look for benefit bulletins or plan amendments from mid-2023 and mid-2024 that explain who approved the change and why. Aggregate plan data on GLP-1 use, spending trends, and adherence could show whether costs are stabilizing. Privacy rules limit personal disclosures, but de-identified reporting can still inform a real debate about value, fairness, and the best way to spend public dollars.
Sources:
x.com, cbsnews.com, nypost.com
